RT @MedPageEndo: What could be the first specific drug to treat osteogenesis imperfecta - a rare genetic #bone-growth disorder - fared pretty well in a phase II trial despite missing one of its primary endpoints, a researcher said at #ASBMR2021. #EndoTwitter https://t.co/NKS9Ex9QiK


from Twitter https://twitter.com/GastonR48222321

October 26, 2021 at 05:23PM

Comentarios

Entradas más populares de este blog

Lunar iDXA